Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05964361 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients(IL15-TransDC) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01719926 | Phase I Platinum Based Chemotherapy Plus Indomethacin(PIFA) | completed | Phase 1 | 13 | UMC UtrechtOTHER | 2 | Jun 4, 2026 |
| clinicaltrials |
| NCT07626996 | Laparoscopic Versus Open Radical Hysterectomy in Early-Stage Cervical Cancer(LAP-OPEN) | completed | N/A | 60 | Zagazig UniversityOTHER_GOV | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 1,560 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04881045 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | completed | Phase 1 | 29 | PfizerINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT00002968 | Edrecolomab in Treating Patients With Stage II Colon Cancer | completed | Phase 3 | 2,100 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06259448 | Feasibility of Optimizing Organized Cervical Cancer Screening by Urine Self-sampling(PAPPEES) | completed | N/A | 173 | University Hospital, BordeauxOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04345003 | MR Elastography Parameters Impact on MR-HIFU Efficacy in Uterine Fibroids(ELASTUS) | completed | N/A | 40 | University Hospital, BordeauxOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06106165 | Improving Muslim Women's Uptake of Cancer Screening (IMCAN)(IMCAN) | completed | N/A | 169 | University of SunderlandOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612865 | People's Hospital of Xinjiang Uygur Autonomous Region | completed | N/A | 160 | People's Hospital of Xinjiang Uygur Autonomous RegionOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05918042 | A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation(OVARD) | completed | — | 414 | AstraZenecaINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT02755844 | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients(ENDOLA) | completed | Phase 1 / Phase 2 | 35 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06010160 | Game Changers for Cervical Cancer Prevention(GC-CCP) | completed | N/A | 936 | RANDOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05044975 | Improving Sleep in Gynecologic Cancer Survivors | completed | N/A | 78 | University of ArizonaOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06102252 | Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma | completed | N/A | 60 | Sohag UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03430700 | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer(PROMPT) | completed | Phase 2 | 20 | University College, LondonOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04008095 | Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer(COLTEP) | completed | — | 40 | University Hospital, BrestOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02386137 | Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids(PERAGUS) | completed | N/A | 40 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04214210 | The DIALOGUE Study: Swiss-Korean Billateral Collaboration(DIALOGUE) | completed | N/A | 128 | University of BaselOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04295577 | Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR(MONITOR-UK) | completed | — | 388 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT00959647 | A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | completed | Phase 2 | 19 | Genentech, Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04726319 | Family History App in Personalized Medicine(FHAMe) | completed | N/A | 627 | University of TorontoOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05409872 | Effects of Vitamin D, Epigallocatechin Gallate, Vitamin B6, and D-Chiro-inositol Combination on Uterine Fibroids(DEFIB) | completed | N/A | 108 | Universita di VeronaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07567573 | Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery(retroESGO ov1) | completed | — | 11,383 | European Society of Gynaecological OncologyOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04739527 | Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment(ALISON) | completed | Phase 1 | 17 | University Medical Center GroningenOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05613088 | A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 9 | Apr 30, 2026 | clinicaltrials |
| NCT07547267 | The Effect of Vaginal Dilator Use | completed | N/A | 80 | Istanbul Aydın UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04185389 | Long-Term Follow-Up of HPV FOCAL Participants(HPV FOCAL) | completed | — | 1,710 | University of British ColumbiaOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05156268 | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | completed | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04716127 | A Proximity-incentive Strategy for Cervical Cancer Screening(RIDECA) | completed | N/A | 656 | University Hospital, MontpellierOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02109367 | Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass | completed | — | 52 | Southern Illinois UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03556839 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix(BEATcc) | completed | Phase 3 | 410 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 8 | Apr 21, 2026 | clinicaltrials |
| NCT03732768 | Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis | completed | Phase 1 | 21 | Oncoinvent Solutions ASINDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT03935282 | Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors(AH-HA) | completed | N/A | 645 | Wake Forest University Health SciencesOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05489978 | Effectiveness of a Cervical Cancer Stigma Reduction Intervention Program on Cancer Stigma Score and Cervical Cancer Screening Uptake in Nepal | completed | N/A | 310 | Kathmandu University School of Medical SciencesOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02854215 | Cost Utility of Radical Surgery in Ovarian Cancer(CURSOC) | completed | N/A | 200 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05132114 | Large Loop Excision of the Transformation Zone (LLETZ) With vs Without IntraOperative Application of Lugol's Iodine(LLETZ-IOLI) | completed | N/A | 230 | Ruhr University of BochumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03115398 | A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery | completed | N/A | 166 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO](ENGOT-EN5) | completed | Phase 3 | 263 | Karyopharm Therapeutics IncINDUSTRY | 10 | Apr 13, 2026 | clinicaltrials |
| NCT03694262 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)(EndoBARR) | completed | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05021562 | A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice | completed | — | 354 | TakedaINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05651282 | Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer(RESToRE) | completed | Phase 4 | 96 | University of British ColumbiaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06274541 | Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study | completed | — | 200 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06973161 | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | completed | — | 140 | AstraZenecaINDUSTRY | 12 | Apr 8, 2026 | clinicaltrials |
| NCT01989923 | Smoking Cessation in Women With Gynecological Conditions | completed | N/A | 31 | University of OklahomaOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03612791 | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab(ATEZOLACC) | completed | Phase 2 | 189 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06919627 | Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)(PaPCR) | completed | — | 45 | University Hospital, BrestOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04122235 | The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study(LETSGO) | completed | N/A | 755 | Sorlandet Hospital HFOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2026source: clinicaltrials